Press Releases

Board change

Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director,… Read More

Read more

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016.

From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver… Read More

Read more

Business Update

  Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, is pleased to announce the following business update. Read More

Read more